Market LIVE
Published markets; coverage varies by country
Product profile · United States

FAMOTIDINE

 ·  Patent Litigation & Settlement History ↓

IngredientFAMOTIDINE
Application typeNDA
Application219935
Product003
Dosage formSOLUTION
RouteINTRAVENOUS
Strength200MG/50ML (4MG/ML)
Approval date2025-07-16
Marketing statusDiscontinued
Status event—
ApplicantSAGENT
Product source

Current GenericRadar decision

Year2026
SelectionDISQUALIFIED
ReviewFINAL
Anchor typeFDA_MARKETING_STATUS
Anchor date—
Patent anchor2001-04-15
Exclusivity anchor—
Protection date2001-04-15
First Final ANDA—
Status event—

Disqualified based on FDA discontinued status; target year uses the documented discontinuation event.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
US42834082001-04-15HISTORICAL_REFERENCE_NOT_EXACT_OB —YNTRUE_DS
Claim 4 covers the famotidine compound. FDA ANDA 75311 chemistry review records the base date 2000-10-15 and PED date 2001-04-15.
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-13 · NO_REGULATORY_EXCLUSIVITY_IDENTIFIED · Historical coverage: ANNUALS_AND_MONTHLY_REVIEWED

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Decision evidence (2)
TypeDateRoleBasisSource
PATENT2001-04-15CANONICAL_ANCHORClaim 4 covers the famotidine compound. FDA ANDA 75311 chemistry review records the base date 2000-10-15 and PED date 2001-04-15.Source
REGULATORY_STATUS—TERMINAL_STATUSDisqualified based on FDA discontinued status; target year uses the documented discontinuation event.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.